Latest News

Latest News

2016 CLLSA Glasgow Members Meeting

There were 4 medical presentations: two given by
Dr Alison McCraig Affiliate (Paul O'Gorman Leukaemia Research Centre) Glasgow University

as well as presentations by

Dr Emilio Cosimo Research Associate (Paul O'Gorman Leukaemia Research Centre) Glasgow University
Dr Ailsa Holroyd Clinical Research Fellow (Institute of Cancer Sciences) Glasgow University.

The presentations can be found here

European Medical Agency - Rixathon

European Medical Agency - On 21 April 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Rixathon, intended for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

NICE says YES to Ibrutinib to treat England and Wales NHS CLL patients

CLLSA are extremely pleased by the NICE decision to approve Ibrutinib to treat NHS England and Wales chronic lymphocytic leukaemia patients.

Today’s Final Appraisal Determination (FAD) recommends that:

1.1Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:

· who have had at least 1 prior therapy or

Blood Cancer Alliance unites to demand NHS England reinstate recently suspended treatments for blood cancer patients.

CLL Support Association is member of the Blood Cancer Alliance and supports the demand for the reinstatement of recently halted therapies by NHS England; in particular reinstatement of stem cell transplants for patients with a rare blood cancer Waldenstroms Macroglobulinaemia (WM)..

Yesterdays letter and the BCA demand

 Sir

The Scottish Medicines Consortium (SMC) accepts ibrutinib (Imbruvica) for restricted use by NHS Scotland to treat 17p TP53 CLL patients

During 2016 CLLSA and patients have worked hard with other stakeholders to capture the patient and carer perspective and deliver this during the appraisal of Ibrutinib by The Scottish Medicines Consortium (SMC). Yesterday SMC announced that ibrutinib (Imbruvica) has been approved for restricted use by NHS Scotland to treat 17p TP53 CLL patients

Tribute to Tricia Gardom

We are very sorry to tell members that our friend and colleague Tricia Gardom died on Wednesday 8th June.

Tricia was a CLLSA member from 2006 and absolutely dedicated to fighting for people affected CLL and raising awareness of our plight. Even when so unwell over her last several months Tricia was there to help others in our on-line community